Juliana Wu1, Jennifer S Ginsberg1, Min Zhan2, Clarissa J Diamantidis1, Jingjing Chen1, Corinne Woods3, Jeffrey C Fink4. 1. Departments of Medicine and. 2. Epidemiology and Public Health, School of Medicine, University of Maryland, Baltimore, Maryland; and. 3. Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore. 4. Departments of Medicine and jfink@medicine.umaryland.edu.
Abstract
BACKGROUND AND OBJECTIVES: Chronic pain in predialysis CKD is not fully understood. This study examined chronic pain in CKD and its relationship with analgesic usage. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data include baseline visits from 308 patients with CKD enrolled between 2011 and 2013 in the Safe Kidney Care cohort study in Baltimore, Maryland. The Wong-Baker FACES Pain Rating Scale measured chronic pain severity. Analgesic prescriptions and over-the-counter purchases were recorded up to 30 days before visits, and were classified as a drug-related problem (DRP) based on an analgesic's nephrotoxicity and dose appropriateness at participants' eGFR. Participants were sorted by pain frequency and severity and categorized into ordinal groups. Analgesic use and the rate of analgesics with a DRP were reported across pain groups. Multivariate regression determined the factors associated with chronic pain and assessed the relationship between chronic pain and analgesic usage. RESULTS: There were 187 (60.7%) participants who reported chronic pain. Factors associated with pain severity included arthritis, taking ≥12 medications, and lower physical function. Use of nonsteroidal anti-inflammatory drugs was reported by seven participants (5.8%) with no chronic pain. Mild and severe chronic pain were associated with analgesics with a DRP, with odds ratios of 3.04 (95% confidence interval [95% CI], 1.12 to 8.29) and 5.46 (95% CI, 1.85 to 16.10), respectively. The adjusted rate of analgesics with a DRP per participant increased from the group with none to severe chronic pain, with rates of 0.07 (95% CI, 0.04 to 0.13), 0.12 (95% CI, 0.07 to 0.20) and 0.16 (95% CI, 0.09 to 0.27), respectively. CONCLUSIONS: Chronic pain is common in CKD with a significant relationship between the severity of pain and both proper and improper analgesic usage. Screening for chronic pain may help in understanding the role of DRPs in the delivery of safe CKD care.
BACKGROUND AND OBJECTIVES:Chronic pain in predialysis CKD is not fully understood. This study examined chronic pain in CKD and its relationship with analgesic usage. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data include baseline visits from 308 patients with CKD enrolled between 2011 and 2013 in the Safe Kidney Care cohort study in Baltimore, Maryland. The Wong-Baker FACES Pain Rating Scale measured chronic pain severity. Analgesic prescriptions and over-the-counter purchases were recorded up to 30 days before visits, and were classified as a drug-related problem (DRP) based on an analgesic's nephrotoxicity and dose appropriateness at participants' eGFR. Participants were sorted by pain frequency and severity and categorized into ordinal groups. Analgesic use and the rate of analgesics with a DRP were reported across pain groups. Multivariate regression determined the factors associated with chronic pain and assessed the relationship between chronic pain and analgesic usage. RESULTS: There were 187 (60.7%) participants who reported chronic pain. Factors associated with pain severity included arthritis, taking ≥12 medications, and lower physical function. Use of nonsteroidal anti-inflammatory drugs was reported by seven participants (5.8%) with no chronic pain. Mild and severe chronic pain were associated with analgesics with a DRP, with odds ratios of 3.04 (95% confidence interval [95% CI], 1.12 to 8.29) and 5.46 (95% CI, 1.85 to 16.10), respectively. The adjusted rate of analgesics with a DRP per participant increased from the group with none to severe chronic pain, with rates of 0.07 (95% CI, 0.04 to 0.13), 0.12 (95% CI, 0.07 to 0.20) and 0.16 (95% CI, 0.09 to 0.27), respectively. CONCLUSIONS:Chronic pain is common in CKD with a significant relationship between the severity of pain and both proper and improper analgesic usage. Screening for chronic pain may help in understanding the role of DRPs in the delivery of safe CKD care.
Authors: Katherine Gooch; Bruce F Culleton; Braden J Manns; Jianguo Zhang; Helman Alfonso; Marcello Tonelli; Cy Frank; Scott Klarenbach; Brenda R Hemmelgarn Journal: Am J Med Date: 2007-03 Impact factor: 4.965
Authors: Karen Barnett; Stewart W Mercer; Michael Norbury; Graham Watt; Sally Wyke; Bruce Guthrie Journal: Lancet Date: 2012-05-10 Impact factor: 79.321
Authors: Li Wei; Thomas M MacDonald; Claudine Jennings; Xia Sheng; Robert W Flynn; Michael J Murphy Journal: Kidney Int Date: 2013-03-13 Impact factor: 10.612
Authors: Clarissa Jonas Diamantidis; Wanda Fink; Shiming Yang; Marni R Zuckerman; Jennifer Ginsberg; Peter Hu; Yan Xiao; Jeffrey C Fink Journal: J Med Internet Res Date: 2013-11-15 Impact factor: 5.428
Authors: Min Zhan; Wendy L St Peter; Rebecca M Doerfler; Corinne M Woods; Jacob B Blumenthal; Clarissa J Diamantidis; Chi-Yuan Hsu; James P Lash; Eva Lustigova; Erin B Mahone; Akinlolu O Ojo; Anne Slaven; Louise Strauss; Jonathan J Taliercio; Wolfgang C Winkelmayer; Dawei Xie; Jeffery C Fink Journal: Clin J Am Soc Nephrol Date: 2017-08-15 Impact factor: 8.237
Authors: Min Zhan; Rebecca M Doerfler; Dawei Xie; Jing Chen; Hsiang-Yu Chen; Clarissa J Diamantidis; Mahboob Rahman; Ana C Ricardo; James Sondheimer; Louise Strauss; Lee-Ann Wagner; Matthew R Weir; Jeffrey C Fink Journal: Am J Kidney Dis Date: 2020-04-18 Impact factor: 8.860
Authors: Tessa K Novick; Aditya Surapaneni; Jung-Im Shin; G Caleb Alexander; Lesley A Inker; Eric A Wright; Alex R Chang; Morgan E Grams Journal: Clin J Am Soc Nephrol Date: 2019-10-03 Impact factor: 8.237